Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine

EPMA Journal

Alexei Gratchev⁴  Julia Kzhyshkowska³  Olga Kovaleva²  Amanda Mickley¹ 

[1] Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany;Blokhin Cancer Research Center, Moscow, Russia;Laboratory for Translational Cellular and Molecular Biomedicine, Tomsk State University, Tomsk, Russia;Laboratory of the Tumour Stromal Cells Biology, Institute of Carcinogenesis, Blokhin Cancer Research Center, Kashirskoye Shosse 24, Moscow, Russia

关键词: Disease prognosis;    Immune response;    Molecular target;    Metastatic disease;    Biomarker panel;    Predictive, preventive and personalized medicine;    Tumor-associated macrophage;    Epigenetics;    Mutation;    Renal cell carcinoma;    Kidney;   

Others  :  1232437
DOI  :  10.1186/s13167-015-0042-2

 received in 2015-08-19, accepted in 2015-09-18,  发布年份 2015

【 摘 要 】

Kidney cancer is one of the deadliest malignancies due to frequent late diagnosis (33 % or renal cell carcinoma are metastatic at diagnosis) and poor treatment options. There are two major subtypes of kidney cancer: renal cell carcinoma (RCC) and renal pelvis carcinoma. The risk factors for RCC, accounting for more than 90 % of all kidney cancers, are smoking, obesity, hypertension, misuse of pain medication, and some genetic diseases. The most common molecular markers of kidney cancer include mutations and epigenetic inactivation of von Hippel-Lindau (VHL) gene, genes of vascular endothelial growth factor (VEGF) pathway, and carbonic anhydrase IX (CIAX). The role of epigenetic pathways, including DNA methylation and chromatin structure remodeling, was also demonstrated. Immunologic properties of RCC enable this type of tumor to escape immune response effectively. An important role in this process is played by tumor-associated macrophages that demonstrate mixed M1/M2 phenotype. In this review, we discuss molecular and cellular aspects for RCC development and current state of knowledge allowing personalized approaches for diagnostics and prognostic prediction of this disease. A set of macrophage markers is suggested for the analysis of the association of macrophage phenotype and disease prognosis.

【 授权许可】

   
2015 Mickley et al.

【 参考文献 】

• [1]Bukowski RM, Olencki T, Wang Q, Peereboom D, Budd GT, Elson P et al.. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response. J Immunother. 1997; 20(4):301-11.
• [2]Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986; 77(2):351-6.
• [3]Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol. 2009; 21(3):266-71.
• [4]Braga VA. Teaching the renal tubular reabsorption of glucose using two classic papers by Shannon et al. Adv Physiol Educ. 2011; 35(2):114-6.
• [5]Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373(9669):1119-32.
• [6]Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996; 93(20):10595-9.
• [7]Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008; 14(1):90-102.
• [8]Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M et al.. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res. 2005; 11(2 Pt 1):646-55.
• [9]Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K et al.. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002; 94(20):1569-75.
• [10]Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP et al.. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008; 180(3):860-5.
• [11]Rini BI, Rathmell WK, Godley P. Renal cell carcinoma. Curr Opin Oncol. 2008; 20(3):300-6.
• [12]Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 2007; 100(3):556-60.
• [13]Rathmell WK, Godley PA. Recent updates in renal cell carcinoma. Curr Opin Oncol. 2010; 22(3):250-6.
• [14]Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol. 2008; 180(2):510-3.
• [15]Zamparese R, Pannone G, Santoro A, Lo Muzio L, Corsi F, Pedicillo MC et al.. Survivin expression in renal cell carcinoma. Cancer Invest. 2008; 26(9):929-35.
• [16]Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M et al.. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007; 5(6):379-85.
• [17]Hehlgans S, Cordes N. Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance. Am J Cancer Res. 2011; 1(4):521-30.
• [18]Itoi T, Yamana K, Bilim V, Takahashi K, Tomita F. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004; 90(1):200-5.
• [19]Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology. 1998; 51(6):1057-61.
• [20]Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T et al.. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology. 2002; 59(4):615-20.
• [21]Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer. 2008; 98(5):931-40.
• [22]Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol. 2010; 4(1):58-73.
• [23]Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis. 2008; 25(2):183-9.
• [24]Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D et al.. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 2009; 13(8B):2376-85.
• [25]Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D et al.. Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med. 2009; 13(8B):2342-52.
• [26]Juengel E, Bhasin M, Libermann T, Barth S, Michaelis M, Cinatl J et al.. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha. World J Urol. 2011; 29(6):779-86.
• [27]Juengel E, Engler J, Mickuckyte A, Jones J, Hudak L, Jonas D et al.. Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int. 2010; 105(4):549-57.
• [28]Juengel E, Engler J, Natsheh I, Jones J, Mickuckyte A, Hudak L et al.. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer. 2009; 9:161. BioMed Central Full Text
• [29]Seliger B, Schlaf G. Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol. 2007; 17(6):444-50.
• [30]Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T et al.. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens. 2006; 68(4):303-10.
• [31]Seliger B, Dressler SP, Lichtenfels R, Kellner R. Candidate biomarkers in renal cell carcinoma. Proteomics. 2007; 7(24):4601-12.
• [32]Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G et al.. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006; 211(6–8):487-501.
• [33]Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S et al.. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med. 1997; 186(8):1315-22.
• [34]Grabbe S, Bruvers S, Beissert S, Granstein RD. Interferon-gamma inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Leukoc Biol. 1994; 55(6):695-701.
• [35]Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196(3):254-65.
• [36]Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK et al.. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011; 332(6026):243-7.
• [37]Reiter I, Krammer B, Schwamberger G. Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J Immunol. 1999; 163(4):1730-2.
• [38]Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M et al.. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011; 102(7):1424-31.
• [39]Daurkin I, Eruslanov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM et al.. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res. 2011; 71(20):6400-9.
• [40]Gratchev A, Kzhyshkowska J, Kannookadan S, Ochsenreiter M, Popova A, Yu X et al.. Activation of a TGF-beta-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J Immunol. 2008; 180(10):6553-65.
• [41]Eruslanov E, Stoffs T, Kim WJ, Daurkin I, Gilbert SM, Su LM et al.. Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res. 2013; 19(7):1670-80.
• [42]Petrella BL, Vincenti MP. Interleukin-1beta mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein beta. Cancer Med. 2012; 1(1):17-27.
• [43]Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol. 2009; 16(10):801-7.
• [44]Li C, Liu B, Dai Z, Tao Y. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther. 2011; 12(10):872-80.
• [45]Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G et al.. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014; 21(9):3142-50.
• [46]Behnes CL, Bremmer F, Hemmerlein B, Strauss A, Strobel P, Radzun HJ. Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. Virchows Arch. 2014; 464(2):191-6.
• [47]Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24.
• [48]Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer. 2009; 115(10 Suppl):2368-75.
• [49]Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C et al.. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014; 12(4):262-9.
• [50]van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP et al.. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011; 17(3):620-9.
• [51]Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA et al.. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011; 12(12):1143-50.
• [52]Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE et al.. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011; 29(18):2557-64.
• [53]Kim HC, Lee JS, Kim SH, So HS, Woo CY, Lee JL. Sunitinib treatment for metastatic renal cell carcinoma in patients with von Hippel-Lindau disease. Cancer Res Treat. 2013; 45(4):349-53.
• [54]Tsimafeyeu I, Demidov L. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease. J Cancer Res Ther. 2010; 6(4):575-7.
• [55]Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA et al.. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011; 22(12):2661-6.
• [56]Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T et al.. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002; 34(1):58-68.
• [57]Kawakami T, Okamoto K, Ogawa O, Okada Y. Multipoint methylation and expression analysis of tumor suppressor genes in human renal cancer cells. Urology. 2003; 61(1):226-30.
• [58]Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al.. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28(6):1061-8.
• [59]Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012; 3(1):14. BioMed Central Full Text
• [60]Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R et al.. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015; 6(1):9. BioMed Central Full Text